Materialise Q1 Earnings: Can Medical Growth Lift a Divided Company?

LEUVEN, Belgium – April 23, 2026 – As Materialise NV (NASDAQ: MTLS) prepares to release its first-quarter 2026 financial results on May 7, investors and industry analysts are keenly watching for signs of continued momentum. The 3D printing pioneer finds itself in a dichotomous position: its medical technology division is flourishing, setting records and driving growth, while its traditional manufacturing and software segments have been navigating significant macroeconomic headwinds. The upcoming report is poised to be a critical barometer, not only for the company's financial health but also for the broader trends shaping the additive manufacturing industry.

The announcement, scheduled for release before the market opens, will be followed by a conference call with senior management. This discussion will provide the first detailed look into the company's performance in the new year, offering crucial insights into whether the strategic resilience shown in its healthcare applications can continue to counterbalance the volatility experienced in its industrial-facing businesses.

A Look Back at a Turbulent 2025

To understand the stakes for the upcoming Q1 report, one must look at Materialise's performance throughout 2025, a year that painted a picture of two distinct companies operating under one roof. The overarching narrative was one of robust, record-setting growth in the Materialise Medical segment, which was consistently offset by struggles in the Manufacturing and Software divisions. For the full year 2025, total revenue remained stable at €267.6 million, but net profit declined to €7.7 million from €13.4 million in 2024, reflecting the divergent paths of its core units.

The final quarter of 2025 exemplified this trend. Materialise posted a consolidated revenue increase of 6.8% year-over-year, a figure driven almost entirely by the Medical segment's impressive 16.3% revenue surge to a record €37 million. This division alone accounted for 53% of the company's total revenue in the quarter. In stark contrast, the Manufacturing and Software segments saw revenues decrease by 2.4% and 1.3%, respectively. While the company managed to improve its overall Adjusted EBIT significantly in Q4, the underlying weakness in its industrial segments remained a persistent concern.

This pattern was consistent throughout the year. In the first quarter of 2025, the company reported a net loss of €535,000, impacted by unfavorable foreign exchange rates and headwinds in industrial markets, even as the Medical segment grew by a remarkable 18.7%. The story was similar in the second and third quarters, with double-digit medical growth propping up consolidated results against declines in the other two segments. Management consistently pointed to geopolitical turbulence and a challenging macroeconomic environment as the primary culprits for the pressure on its industrial-focused divisions.

Medical Division: The Engine of Growth and Innovation

The standout success of Materialise’s Medical segment is more than just a financial story; it is a narrative of targeted innovation and market leadership in a resilient sector. While other parts of the additive manufacturing industry are sensitive to economic cycles and discretionary spending, the demand for personalized medical devices and surgical planning tools remains strong. Materialise has expertly capitalized on this by establishing itself as a critical partner for healthcare professionals.

Throughout 2025, the company announced several key milestones that underscore its technological prowess. It received 510(k) clearance from the U.S. Food and Drug Administration for a personalized alignment feature within its knee surgery planning software, a significant step in advancing patient-specific orthopedic procedures. Furthermore, a pilot collaboration with Johnson & Johnson's surgical business in Europe, the Middle East, and Africa signaled growing adoption and trust from major players in the medical device industry. The company also reported notable advancements in its cardiac and trauma planners, continuously expanding its portfolio of high-value, clinically-proven solutions.

The segment's financial performance reflects this strategic focus. With an Adjusted EBITDA margin consistently hovering around 30-35%, the Medical division is not just a revenue driver but also a significant contributor to the company's profitability and cash flow. This financial strength allows for sustained investment in research and development, creating a virtuous cycle of innovation that further solidifies its market position.

Navigating Headwinds in Manufacturing and Software

While the Medical segment shines, the Manufacturing and Software divisions have faced a more challenging environment. The Materialise Manufacturing segment, which provides 3D printing services for prototyping and production parts across industries like automotive and aerospace, is directly exposed to broader economic trends. The headwinds cited by management in 2025 translated into decreased demand and revenue declines, leading to a negative Adjusted EBITDA for the segment in every quarter of that year.

The Software segment, long considered the backbone of the 3D printing industry, has been undergoing a significant strategic transformation. Materialise has been shifting its model from perpetual licenses to a cloud-based, subscription-first approach. While this transition is strategically sound for building a more predictable, recurring revenue stream for the long term, it can create short-term revenue volatility. By the start of 2025, the company reported that over 80% of its software revenue was recurring, a positive indicator of the transition's progress. However, the segment still posted revenue declines in several quarters, suggesting the market's adjustment to the new model is ongoing. Investors will be looking for signs in the Q1 2026 report that this transition is beginning to yield more stable top-line growth.

Investor Outlook and Market Expectations

As the May 7th announcement approaches, the investment community holds a cautiously optimistic view. Analyst ratings currently lean towards a 'Buy' consensus with a price target of $8.10. However, AI-driven sentiment analysis reflects the company's dual nature, rating the stock as 'Neutral.' It cites a healthier balance sheet, constructive 2026 guidance, and the powerful Medical segment as key positives, but weighs them against weakening recent top-line trends and a less favorable technical chart setup.

Shareholders will be looking for confirmation of the company's full-year 2026 guidance and will scrutinize the performance of each segment for clues about the year ahead. Key questions loom: Can the Medical segment maintain its blistering pace of double-digit growth? Are there any green shoots of recovery in the industrial-focused Manufacturing segment? And is the Software segment's subscription model beginning to translate into renewed, stable growth?

Management's strategic actions in late 2025, including a successful secondary listing on the Euronext Brussels exchange and the authorization of a share buyback program, were interpreted as signs of confidence in the company's long-term value. The upcoming earnings call will be a crucial opportunity for leadership to reinforce that confidence with concrete data and a clear outlook. The results will ultimately reveal whether Materialise's powerful medical engine can successfully pull the entire company forward through a still-uncertain global economic landscape.